1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Natco Pharma Limited

Natco Pharma Limited

NATCOPHARM.NS
Natco Pharma LimitedIN flagNational Stock Exchange of India
966.30
INR
-17.85
- -
173.07BMarket Cap
Natco Pharma Limited
NATCOPHARM.NS
(National Stock Exchange of India)

Recent

price

966.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
32.66
35.63
41.62
45.83
49.43
62.38
114.51
121.63
111.93
103.76
92.79
104.45
147.73
221.67
247.29
- -
227.72
Revenue per Share
3.69
4.11
4.6
6.43
8.13
9.22
27.89
39.26
34.98
25.33
24.2
9.32
39.18
77.34
105.26
- -
79.2
Basic EPS, GAAP
-4.19
-4.38
-3.23
2.11
-1.6
-2.65
3.81
2.22
11.24
3.23
2.43
-10.76
35.25
47.52
66.17
- -
- -
Free Cash Flow per Basic Share
0.46
0.73
0.92
1.21
1.2
1.53
8.09
10.23
6.02
8.44
6.25
4.51
5.5
9.52
6.02
- -
- -
Dividend per Share
16.24
18.82
20.67
24.85
30.03
35.19
54.2
82.39
107.14
125.07
142.99
148.22
182.35
250.79
350.74
- -
2
Book Value per Share
23.92
31.39
32.99
43.87
48.74
75.98
94.23
173.15
189.04
207.54
225.85
226.5
256.69
315.33
410.13
- -
500.5
Tangible Book Value per Share
141
145
156
160
166
170
174
177
184
182
182
182
183
179
179
- -
179
Basic Weighted Avg Shares
4,597
5,174
6,501
7,321
8,186
10,633
19,951
21,567
20,618
18,878
16,903
19,049
26,969
39,788
44,295
40,783
40,783
Sales/Revenue/Turnover
18.86
18.39
20.29
20.57
20.94
21.72
32.86
40.59
34.82
26.02
29.66
7.39
29.3
39.63
44.27
30.16
30.16
Operating Margin (%)
159
159
221
304
473
510
544
662
810
998
1,169
1,426
1,638
1,868
2,352
2,066
2,066
Depreciation Expense
519
596
719
1,027
1,346
1,571
4,860
6,962
6,444
4,608
4,409
1,700
7,153
13,883
18,854
14,185
14,185
Net Income, GAAP
20.29
26.5
35.61
23.93
2.94
23.77
22.34
21.64
22.11
19.45
23.67
15.92
17.01
17.04
17.81
7.98
7.98
Effective Tax Rate (%)
11.29
11.52
11.06
14.03
16.44
14.77
24.36
32.28
31.25
24.41
26.08
8.92
26.52
34.89
42.56
34.78
34.78
Profit Margin (%)
536
334
-144
559
738
3,439
4,608
15,387
16,185
16,403
18,192
17,763
23,172
30,507
43,265
33,714
33,714
Working Capital
1,254
1,341
1,378
955
970
- -
- -
- -
- -
9
9
80
11
53
46
1,042
1,042
LT Debt
3,535
4,745
5,441
7,328
8,496
13,006
16,534
30,760
34,910
37,847
41,234
42,636
48,738
58,531
76,123
92,211
92,211
Total Equity
14.08
11.28
10.82
12.36
15.55
13.63
30.81
26.69
15.68
9.91
9
2.62
13.52
23.19
22.72
12.66
12.66
Return on Invested Capital (%)
16.78
16.65
16.17
20.27
22.95
22.68
52.94
50.4
32.95
19.19
16.2
6.01
21.78
33.38
33.34
39.7
39.7
Return on Capital (%)
25.24
23.76
24.11
28.55
30.11
28.64
62.95
57.89
37.53
21.69
18.07
6.41
23.72
35.46
34.97
44.9
44.9
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
2,560
- -
6,097
LT Borrowings
- -
- -
1,000
LT Finance Leases
47
- -
42
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
179
- -
179
Market Capitalization
142,473
161,742
174,475

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
69,667
- -
50,523
Cash, Cash Equivalents & STI
40,768
- -
28,709
Accounts Receivable, Net
17,189
- -
8,812
Inventories
8,180
- -
9,085
Total Current Liabilities
17,000
- -
16,809
Payables & Accruals
- -
- -
- -
ST Debt
2,560
- -
6,097
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
23.3%
17.8%
21.13%
Free Cash Flow
-84.1%
-176.83%
16.2%
Net Income, GAAP
57.68%
72.89%
-24.76%
Sales/Revenue/Turnover
17.76%
21.04%
-7.93%
Total Cash Common Dividend
45.37%
2.24%
-16.33%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11,405
10,314
7,586
10,483
39,788
2025
13,626
13,711
4,748
12,210
44,295
2026
13,289
13,630
6,473
7,391
40,783

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
23.26
20.6
11.88
- -
77.34
2025
37.32
37.81
7.43
22.7
105.26
2026
26.84
28.94
8.46
14.96
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
9.52
2025
- -
- -
- -
- -
6.02
2026
- -
- -
- -
- -
- -
Similar Companies
Mountain Valley MD Holdings Inc. (MVMD.CN)
For The Earth Corp. (FTEG)
Marijuana Inc. (MAJI)
Takeda Pharmaceutical Company Limited (TAK)
China Traditional Chinese Medicine Holdings Co. Limited (0570.HK)
CBD Global Sciences Inc. (CBDN.CN)
Business
NATCO Pharma Limited, headquartered in Hyderabad, India, and founded in 1981, develops, manufactures and markets finished dosage formulations, active pharmaceutical ingredients and agrochemicals, with a focus on generic oncology medicines; branded drugs in cardiology, diabetology, gastroenterology, neurology, infectious diseases including HIV and hepatitis C, orthopedics and rheumatology; and niche products such as chemotherapy agents, targeted therapies, antiviral medications, central nervous system treatments, cardiovascular drugs and biosimilars for cancer and autoimmune conditions. The company operates facilities in Telangana and Andhra Pradesh, supplies APIs to other pharmaceutical firms, provides contract manufacturing services and exports to over 50 countries spanning North America, Europe, Asia-Pacific and emerging markets. In 2025, NATCO completed its strategic acquisition of a 35.75% stake in South Africa's Adcock Ingram Holdings Limited for approximately Rs 2000 crore, marking entry into the African pharmaceutical market and leveraging the target's established presence for expanded revenue streams and regional growth; it also launched generic versions of complex blockbusters like Glatiramer Acetate for multiple sclerosis in the US and continues portfolio expansion in specialty formulations and crop health sciences with products such as chlorantraniliprole-based agrochemicals.